Meeting
2022 ASCO Annual Meeting
Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.
Authors
Naoki Nakamura
Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
Naoki Nakamura , Yuka Kato , Go Makimoto , Kiichiro Ninomiya , Daijiro Harada , Takashi Ninomiya , Isao Oze , Toshio Kubo , Masanori Fujii , Eiki Ichihara , Kadoaki Ohashi , Toshiyuki Kozuki , Katsuyuki Hotta , Masahiro Tabata , Katsuyuki Kiura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Clinical Trial Registration Number
061210047
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS12141)
DOI
10.1200/JCO.2022.40.16_suppl.TPS12141
Abstract #
TPS12141
Poster Bd #
383b
Abstract Disclosures
Similar Posters
Poster
2014 Palliative and Supportive Care in Oncology Symposium
Relationship of peripheral neuropathy grades with increase of skin perfusion by compression therapy for breast cancer patients.
First Author: Tsuyoshi Ohno
Poster
2014 Palliative and Supportive Care in Oncology Symposium
Effect of duloxetine on chemotherapy-induced painful peripheral neuropathy.
First Author: Yasuo Hirayama
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim